Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How Do You Know If A REMS Is Effective? Look At Postmarket Data, Surveys, Patient Access

Executive Summary

US FDA draft guidance describes how to determine if a Risk Evaluation and Mitigation Strategy is meeting its goals; another guidance advises how to conduct REMS knowledge surveys.

You may also be interested in...



Drug Safety: FDA Pushes To Publicly Release REMS Assessments, Says It Will Improve Plan Design

Proposal would allow stakeholders to see data on REMS goals like provider training and the US FDA’s conclusions about their effectiveness.

Waivers For Shared REMS Will Depend On Impact To Generics, Docs, Patients

US FDA will take multiple factors into account when deciding whether single shared-system REMS requirement is necessary.

Shared REMS: US FDA Wants Brisk Brand-Generic Talks, Might Give Unilateral Waivers

New draft guidances are an attempt to curb abuse of REMS single shared system process to delay generic entry.

Topics

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel